Cabozantinib in advanced adrenocortical carcinoma showed promising efficacy with a manageable and anticipated safety profile. Further prospective studies with cabozantinib alone and in combination with immune checkpoint therapy are ongoing.
[Articles] Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial
For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –
LATEST
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
Privacy Policy